Journal article · 2023 · Open access

Potent Rifampicin derivatives can clear MRSA infections at single low doses when concomitantly dosed with Vancomycin

Thomas Nittoli, Anna Brotcke, Abira Bandyopadhyay, Stephanie Federici, Alida Coppi, Susan Jorgenson, Seung-Yong Choi, Mrinmoy Saha, Benjamin Wertz, Priyanka Trivedi, Chandrashekhar K. Korgaonkar, Harvey Chin and 3 more

The Journal of Antibiotics, 77(1), 57–65 · Published 23 October 2023 · DOI 10.1038/s41429-023-00663-6

Open PDFView at the publisherCite this paper

In brief

“Potent Rifampicin derivatives can clear MRSA infections at single low doses when concomitantly dosed with Vancomycin” is a 2023 journal article by Thomas Nittoli and 14 co-authors, published in The Journal of Antibiotics. OpenAlex counts 0 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at The Journal of Antibiotics.

Citations
0
References
13
Authors
15

Abstract

For a number of years, antimicrobial resistance (AMR) has been a critical issue for humanity. Drug discovery efforts have been very limited and the spread of bacterial pathogens has over-run our traditional arsenal of antibiotics. Bacteria can involve to evade compounds that can halt their rapid growth. The authors have discovered a potent macrocycle derivative that when dosed concomitantly with the standard of care (SOC) antibiotic vancomycin, can clear methicillin resistant Staphylococcus aureus (MRSA) infections. In addition, we have probed the lead compounds in Salmonella typhimurium bacterial strains. In vitro, in vivo, and ADME data have been included to stress the virtues of this new antibiotic.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Nittoli, T., Brotcke, A., Bandyopadhyay, A., Federici, S., Coppi, A., Jorgenson, S., Choi, S.-Y., Saha, M., Wertz, B., Trivedi, P., Korgaonkar, C. K., Chin, H., Luong, O., Kyratsous, C. A., & Olson, W. C. (2023). Potent Rifampicin derivatives can clear MRSA infections at single low doses when concomitantly dosed with Vancomycin. The Journal of Antibiotics, 77(1), 57–65. https://doi.org/10.1038/s41429-023-00663-6

MLA 9

Nittoli, Thomas, et al. “Potent Rifampicin derivatives can clear MRSA infections at single low doses when concomitantly dosed with Vancomycin.” The Journal of Antibiotics, vol. 77, no. 1, 2023, pp. 57–65. https://doi.org/10.1038/s41429-023-00663-6.

Chicago

Nittoli, Thomas, Anna Brotcke, Abira Bandyopadhyay, Stephanie Federici, Alida Coppi, Susan Jorgenson, Seung-Yong Choi, et al. 2023. “Potent Rifampicin derivatives can clear MRSA infections at single low doses when concomitantly dosed with Vancomycin.” The Journal of Antibiotics 77 (1): 57–65. https://doi.org/10.1038/s41429-023-00663-6.

Harvard

Nittoli, T. et al. (2023) ‘Potent Rifampicin derivatives can clear MRSA infections at single low doses when concomitantly dosed with Vancomycin’, The Journal of Antibiotics, 77(1), pp. 57–65. doi:10.1038/s41429-023-00663-6.

IEEE

T. Nittoli et al., “Potent Rifampicin derivatives can clear MRSA infections at single low doses when concomitantly dosed with Vancomycin,” The Journal of Antibiotics, vol. 77, no. 1, pp. 57–65, 2023, doi: 10.1038/s41429-023-00663-6.

BibTeX

@article{nittoli2023potent,
  title     = {{Potent Rifampicin derivatives can clear MRSA infections at single low doses when concomitantly dosed with Vancomycin}},
  author    = {Nittoli, Thomas and Brotcke, Anna and Bandyopadhyay, Abira and Federici, Stephanie and Coppi, Alida and Jorgenson, Susan and Choi, Seung-Yong and Saha, Mrinmoy and Wertz, Benjamin and Trivedi, Priyanka and Korgaonkar, Chandrashekhar K. and Chin, Harvey and Luong, Onson and Kyratsous, Christos A. and Olson, William C.},
  journal   = {The Journal of Antibiotics},
  year      = {2023},
  volume    = {77},
  number    = {1},
  pages     = {57--65},
  doi       = {10.1038/s41429-023-00663-6},
  url       = {https://doi.org/10.1038/s41429-023-00663-6}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus

  • methicillin-resistant Staphylococcus aureus
  • MRSA infection
  • vancomycin
  • combination antibiotic therapy
  • antimicrobial resistance
  • Salmonella typhimurium
  • ADME profiling

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Nittoli, T., Brotcke, A., Bandyopadhyay, A., Federici, S., Coppi, A., Jorgenson, S., Choi, S.-Y., Saha, M., Wertz, B., Trivedi, P., Korgaonkar, C. K., Chin, H., Luong, O., Kyratsous, C. A., & Olson, W. C. (2023). Potent Rifampicin derivatives can clear MRSA infections at single low doses when concomitantly dosed with Vancomycin. The Journal of Antibiotics, 77(1), 57–65. https://doi.org/10.1038/s41429-023-00663-6

How many times has this paper been cited?

0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The Journal of Antibiotics: sign in and open the PDF from this page.

Who wrote this paper?

Thomas Nittoli, Anna Brotcke, Abira Bandyopadhyay, Stephanie Federici, Alida Coppi, Susan Jorgenson, Seung-Yong Choi, Mrinmoy Saha, Benjamin Wertz, Priyanka Trivedi, Chandrashekhar K. Korgaonkar, Harvey Chin and 3 more.

What is the DOI of this paper?

10.1038/s41429-023-00663-6, permanently at https://doi.org/10.1038/s41429-023-00663-6. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.